NCT05013437 2024-04-02
AHCT
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
14 trialsNCT04466475 2024-01-31
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03003728 2020-07-10
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
University of Arkansas
Phase 2 Withdrawn
NCT03328936 2020-02-21
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03100877 2017-12-13
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT01251172 2017-09-28
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT02447055 2016-07-12
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Withdrawn
NCT01055301 2015-03-06
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00968396 2013-04-05
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00577668 2011-05-03
A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
University of Arkansas
Phase 2 Withdrawn